00:00U.S. stock futures were mixed on Monday, as the Dow Jones and S&P 500 indices rose,
00:05while the Nasdaq 100 index fell, following Friday's higher close.
00:10Geopolitical tensions flared over the weekend as Iran stepped up attacks on shipping near
00:14the Strait of Hormuz and threatened regional digital infrastructure,
00:18citing an inadequate U.S. response to its peace terms.
00:21The escalation comes amid reports that Tehran rejected Washington's latest proposals to end
00:26the conflict, with prediction markets signaling low odds of a near-term diplomatic resolution
00:31to reopen the strategic waterway. Attention on Wall Street is turning toward third-quarter
00:36earnings reports. Meanwhile, the 10-year Treasury bond yield stood at 5.24%,
00:41and the two-year Treasury bond yield was at 4.79% as of Friday's close.
00:46The CME Group's FedWatch tool projections show markets pricing in an 18.8% likelihood
00:52of the Federal Reserve hiking interest rates after its October meeting.
00:57The SPDR S&P 500 ETF Trust and Invesco QQQ Trust ETF were mixed in pre-market trading on Monday.
01:04The SPY rose by 0.23% to $780.35, while the QQQ declined 0.024% to $751.09.
01:16Stocks in focus for today are Standard Motor Products fell 3.14% in pre-market trading on Monday,
01:24as it named James J. Burke as interim CFO, effective October 30, succeeding Nathan R. Iles.
01:32Quantum was 2.71% lower in Monday pre-market, as it terminated William H. White as CFO,
01:38and principal financial officer, effective October 9, 2026.
01:43The company named Heerol A. Patel as principal financial officer.
01:48JSTAR Holding surged 153.49% after the company announced its ongoing corporate capital initiatives
01:55will fund the planned U.S. expansion for drone frame manufacturing.
02:00SVRN jumped 15.89% after the company announced it acquired FastNear,
02:06a provider of remote procedure call infrastructure that supports applications on the NIR protocol.
02:11FirstTrack's biotherapeutics was 18.68% higher after it said that it will announce top-line data
02:18from Cohort 1 of Phase 1B trial of ANB-033, a CD122 antagonist, in celiac disease on October 12.
02:27Thank you for watching and make sure to subscribe.
Comments